|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 82.70 EUR | -1.01% |
|
+0.32% | -11.78% |
| 07-11 | SANOFI : UBS reiterates its Buy rating | ZD |
| 07-10 | Delaware Supreme Court sides with Zantac drugmakers over cancer evidence | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability (Composite) | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
| 119B | ||||||
| 718B | ||||||
| 377B | ||||||
| 338B | ||||||
| 308B | ||||||
| 259B |
- Stock Market
- Equities
- SAN Stock
- Charts Sanofi
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition